Pharmacophore mapping studies on indolizine derivatives as 15-LOX inhibitors

Funk, 1996, The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice, Biochim Biophys Acta Lipids Lipid Metab, 1304, 65, 10.1016/S0005-2760(96)00107-5 Cyrus, 2001, Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice, Circulation, 103, 2277, 10.1161/01.CIR.103.18.2277 George, 2001, 12/15-lipoxygenase gene disruption attenuates atherogenesis in ldl receptor–deficient mice, Circulation, 104, 1646, 10.1161/hc3901.095772 Witztum, 2001, The oxidative modification hypothesis of atherosclerosis: does it hold for humans, Trends Cardiovasc Med, 11, 93, 10.1016/S1050-1738(01)00111-6 Funk, 2001, 12/15-Lipoxygenase, oxidative modification of LDL and atherogenesis, Trends Cardiovasc Med, 11, 116, 10.1016/S1050-1738(01)00096-2 Weaver, 2001, Increased 15-HPETE production decreases prostacyclin synthase activity during oxidant stress in aortic endothelial cells, Free Radical Biol Med, 30, 299, 10.1016/S0891-5849(00)00466-4 Kelavkar, 2000, Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with gleason staging, Carcinogenesis, 21, 1777, 10.1093/carcin/21.10.1777 Kelavkar, 2001, Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis, Carcinogenesis, 22, 1765, 10.1093/carcin/22.11.1765 Shureiqi, 1999, Decreased 13-S-hydroxyoctadecadienoic acid levels and 15- lipoxygenase-1 expression in human colon cancers, Carcinogenesis, 120, 1985, 10.1093/carcin/20.10.1985 Sharma, 2014, Indolizine: a biologically active moiety, Med Chem Res, 23, 3593, 10.1007/s00044-014-0940-1 Sharma, 2010, Biological importance of the indole nucleus in recent years: a comprehensive review, J Het Chem, 47, 491 Sharma, 2013, Heterocyclic chalcone analogues as potential anticancer agents, Anticancer Agents Med Chem, 13, 422 Gundersen, 2003, Indolizines as novel potent inhibitors of 15-lipoxygenase, Bioorg Med Chem, 11, 5409, 10.1016/j.bmc.2003.09.033 Wermuth, 1998, Glossary of Terms Used in Medicinal Chemistry (IUPAC Recommendations 1997), Ann Rep Med Chem, 33, 385, 10.1016/S0065-7743(08)61101-X Yang, 2010, Pharmacophore modeling and applications in drug discovery: challenges and recent advances, Drug Discovery Today, 15, 444, 10.1016/j.drudis.2010.03.013 Cruz, 2014, 3D-QSAR as a tool for understanding and improving single-site polymerization catalysts. a review, Organometallics, 33, 2944, 10.1021/om400721v Hariprasad, 1996, A proposed common spatial pharmacophore and the corresponding active conformations of some peptide leukotriene receptor antagonists, J Comp Aid Mol Des, 10, 284, 10.1007/BF00124498 Maestro, Version 8.5, Schrodinger, LLC, NY2008. PHASE, Version 3.0, Schrodinger, LLC, NY2008. Kaushik, 2012, Computation of pharmacophore models for the prediction of mitogen-activated protein kinase activated protein kinase-2 inhibitory activity of pyrrolopyridines, Med Chem Res, 21, 3777, 10.1007/s00044-011-9910-z Rani, 2011, Development of pharmacophore models for predicting HIV-1 reverse transcriptase inhibitory activity of pyridinone derivatives, Pharm Chem J, 45, 36, 10.1007/s11094-011-0556-4 Goyal, 2011, Pharmacophore modeling studies on aryl thioxothiazolidinones as ADAMTS-5 (Aggrecanase-2) inhibitors, Der Pharma Chem, 3, 448